✦ LIBER ✦

Folliculitis spinulosa decalvans: failure to respond to oral isotretinoin

✍ Scribed by N Hallai; I Thompson; P Williams; AVA Anstey

Book ID: 111094326
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 128 KB
Volume: 20
Category: Article
ISSN: 0926-9959
DOI: 10.1111/j.1468-3083.2005.01367.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Familial eruptive sebaceous hyperplasia

Familial eruptive sebaceous hyperplasia responded to oral isotretinoin

📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Failure to respond to IV metoclopramide

Failure to respond to IV metoclopramide at gastric emptying scan does not predict failure of clinical response to oral prokinetics

✍ Remi R. Owo; Lawrence K. Gates 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 172 KB

A genetically determined lack of oral to

A genetically determined lack of oral tolerance to ovalbumin is due to failure of the immune system to respond to intestinally derived tolerogen

✍ Allan McI. Mowat; Alan G. Lamont; Maureen G. Bruce 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 408 KB

A genetically determined lack of oral tolerance to ovalbumin is due to failure of the immune system to respond to intestinally derived tolerogen\* In this study we have examined whether differences between mouse strains in the induction of tolerance after feeding ovalbumin (OVA) are due to differen

Effects of a combination of bedtime inte

Effects of a combination of bedtime intermediate-acting insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to respond to oral hypoglycaemic agents

✍ M. Krempf; T. Godeau; S. Ranganathan; P. Blanchard; P. Ritz; B. Charbonnel 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 603 KB

The effect of a subcutaneous injection of an intermediate-acting insulin at bedtime combined with glibenclamide has been evaluated in 16 non-insulin-diabetic patients with secondary failure to respond to oral agents. The patients showed poor metabolic control (HbA1 greater than 11%) after two months